Update on methotrexate as the anchor drug for rheumatoid arthritis

Bulletin of the Hospital for Joint Diseases

Volumn 71, Issue , 2013, Pages S9-S19

  Pincus, Theodore ^a   Gibson, Kathryn A ^b   Castrejón, Isabel ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LIVERPOOL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFORMATION PROCESSING; META ANALYSIS; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888358290     PISSN: 23284633     EISSN: 23285273     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Pincus T, Yazici Y, Sokka T, et al. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S179-85.
2. Visser K, Katchamart W, Loza E, et al. Multinational evidence- based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009 Jul;68(7):1086-93. doi: 10.1136/ard.2008.094474. Epub 2008 Nov 25.
3. Pincus T, Cronstein B, Braun J. Methotrexate—the anchor drug—an introduction. Clin Exp Rheumatol. 2010 Sep- Oct;28(5 Suppl 61):S1-S2.
4. Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007 Nov;66:1491-6.
5. Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984 Aug;27:864-72.
6. Rasker JJ, Cosh JA. The natural history of rheumatoid arthritis: a fifteen year follow-up study. The prognostic significance of features noted in the first year. Clin Rheumatol. 1984 Mar;3:11-20.
7. Scott DL, Grindulis KA, Struthers GR, et al. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis. 1984 Feb;43:8-17.
8. Sokka T, Kautiainen H, Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis. Ann Rheum Dis. 2007 Mar;66(3):341-4.
9. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med. 1980 Oct;93:551-6.
10. Scott DL, Coulton BL, Chapman JH, et al. The long-term effects of treating rheumatoid arthritis. J R Coll Physicians Lond. 1983 Jan;17(1):79-85.
11. Bergstrom U, Book C, Lindroth Y, et al. Lower disease activity and disability in Swedish patients with rheumatoid arthritis in 1995 compared with 1978. Scand J Rheumatol. 1999;28(3):160-5.
12. Sokka TM, Kaarela K, Möttönen TT, Hannonen PJ. Conventional monotherapy compared to a “sawtooth” treatment strategy in the radiographic procession of rheumatoid arthritis over the first eight years. Clin Exp Rheumatol. 1999 Sep-Oct; 17(5): 527-32.
13. Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med. 2003 Oct 1;115:371-6.
14. Sokka T, Kautiainen H, Häkkinen K, Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol. 2004 Jun;31(6):1073-82.
15. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum. 2005 Apr;52:1009-19.
16. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum. 2000 Jan;43(1):14-21.
17. Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002 Apr 6;359(9313):1173-7.
18. Wilske KR, Healey LA. Remodeling the pyramid - a concept whose time has come. J Rheumatol. 1989 May;16(5):565-7.
19. Pincus T, Callahan LF. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis - lessons from Hodgkin’s disease and coronary artery disease. J Rheumatol. 1990 Dec;17(12):1582-5.
20. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the “sawtooth” strategy. J Rheumatol Suppl. 1990 May;17(Suppl 22):12-5.
21. Pincus T. The case for early intervention in rheumatoid arthritis. J Autoimmun. 1992 Apr;5 Suppl A: 209-26.
22. Pincus T. Rheumatoid arthritis: A medical emergency? Scand J Rheumatol. 1994; 23(Suppl 100):21-30.
23. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis. 1995 Dec;54(12):944-7.
24. Weinblatt ME. Rheumatoid arthritis: Treat now, not later! (editorial). Ann Intern Med. 1996 Apr 15;124(8):773-4.
25. Emery P, Panayi G, Sturrock R, Williams B. Targeted therapies in rheumatoid arthritis: The need for action. Rheumatology (Oxford). 1999 Oct;38(10):911-2.
26. Pincus T, Sokka T, Kavanaugh A. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for “near remission” of DAS or single measures. Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S50-6.
27. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010 Apr;69(4):631-7.
28. Silman A, Davies P, Currey HLF, Evans SJW. Is rheumatoid arthritis becoming less severe? J Chronic Dis. 1983;36(12):891-7.
29. Silman AJ. Trends in the incidence and severity of rheumatoid arthritis. J Rheumatol Suppl. 1992 Jan;32:71-3.
30. Uhlig T, Kvien TK. Has rheumatoid arthritis become a milder disease? Drug Discovery Today. 2005;2(3):331-6.
31. Pincus T, Furer V, Sokka T. Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients. Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S68-79.
32. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum. 1990 Oct;33(10):1449-61.
33. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: survey of 71 “negative” trials. N Engl J Med. 1978 Sep 28;299(13):690-4.
34. Freireich EJ. The randomized clinical trial as an obstacle to clinical research. In: Varco RL, Delaney JP (eds): Controversy in Surgery (2nd ed). Philadelphia: W.B. Saunders, 1983, pp. 5-12.
35. Feinstein AR. An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med. 1983 Oct;99(4):544-50.
36. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet. 1995 Jun 24;345(8965):1616-9.
37. Feinstein AR, Horwitz RI. Problems in the “evidence” of “evidence-based medicine.” Am J Med. 1997 Dec;103(6):529-35.
38. Kaptchuk TJ. The double-blind, randomized, placebo-controlled trial: gold standard or golden calf? J Clin Epidemiol. 2001 Jun;54(6):541-9.
39. Siderowf AD. Evidence from clinical trials: can we do better? NeuroRx. 2004 Jul;1(3):363-71.
40. Kemm J. The limitations of “evidence-based” public health. J Eval Clin Pract. 2006 Jun;12(3):319-24.
41. Mack MJ. Clinical trials versus registries in coronary revascularization: which are more relevant? Curr Opin Cardiol. 2007 Nov;22(6):524-8.
42. Sanson-Fisher RW, Bonevski B, Green LW, D’Este C. Limitations of the randomized controlled trial in evaluating population-based health interventions. Am J Prev Med. 2007 Aug;33(2):155-61.
43. Vandenbroucke J. When are observational studies as credible as randomised trials? Lancet. 2004 May 22;363(9422):1728-31.
44. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol. 1988;41(11):1037-41.
45. Pincus T, Wolfe F. Response to letter: Gold therapy for rheumatoid arthritis: Challenges to traditional paradigms. Ann Intern Med. 1992;117:169-70.
46. Pincus T. Limitations of randomized controlled clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum. 1993 Oct;23(2 Suppl 1):2-10.
47. Pincus T, Stein M. What is the best source of useful data on the treatment of rheumatoid arthritis: Clinical trials, clinical observations, or clinical protocols? J Rheumatol. 1995 Sep;22(9):1611-7.
48. Pincus T. Analyzing long-term outcomes of clinical care without randomized controlled clinical trials: The consecutive patient questionnaire database. Advances. 1997;13:3-32.
49. Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies. Clin Exp Rheumatol. 1997 May-Jun;15 Suppl.17:S27-38.
50. Pincus T, Sokka T. Clinical trials in rheumatic diseases: designs and limitations. Rheum Dis Clin North Am. 2004 Nov;30(4):701-24, v-vi.
51. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006 Jan;129(1):174-81.
52. Pincus T, Yazici Y, Sokka T. Are excellent systematic reviews of clinical trials useful for patient care? Nat Clin Pract Rheumatol. 2008 Jan;4:294-5.
53. Pincus T. Sokka T. Evidence-based practice and practice-based evidence. Nat Clin Pract Rheumatol. 2006;2(3):114-5.
54. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. Oxford, UK, 2011.Available at: www.cebm.net/index.aspx?o=5653.
55. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of diseasemodifying medications for rheumatoid arthritis. Ann Intern Med. 2008 Jan 15;148(2):124-34.
56. Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second-line drugs and prednisone. J Rheumatol. 1992 Dec;19(12):1885-94.
57. Williams HJ, Ward JR, Reading JC, et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum. 1992 Mar;35(3):259-69.
58. Yazici Y, Sokka T, Kautiainen H, et al. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis. 2005 Feb;64(2):207-11.
59. Boers M. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? Arthritis Rheum. 2003 Jun;48(6):1481-3.
60. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. Lancet. 1999;354:1932-9.
61. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586-93.
62. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor α antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
63. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002 Jun;46(6):1443-50.
64. Pincus T. RAPID3, an index of only 3 patient self-report Core Data Set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis. Bull Hosp Jt Dis. 2013;71(2):117-20.
65. Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. J Rheumatol. 2005 Aug;32(80):1432-9.
66. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: Proposed severity categories compared to DAS and CDAI categories. J Rheumatol. 2008 Nov;35(11):2136-47.
67. Pincus T, Castrejón I. Evidence that the strategy more important than the agent to treat rheumatoid arthritis: data from clinical trials with a tight control or treat-to-target protocol. Bull Hosp Jt Dis. 2013;71(Suppl 2):S33-40.
68. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004 Jul 17-23; 364(9430): 263-9.
69. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005 Nov;52(11):3381-90.
70. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997 Aug 2;350(9074):309-18.
71. Verstappen SMM, Jacobs JWG, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007 Nov;66(11):1443-9.
72. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis. 2008 Jun;67(6):815-22.
73. Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012 Sep;64(9):2824-35.
74. van der Heijde D, Landewe R, Klareskog L, et al. Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study. Arthritis Rheum. 2005 Jan;52(1):49-60.
75. St. Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004 Nov;50(11):3432-43.
76. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 Jan;54(1):26-37.
77. Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum. 2002 Apr;46(4):913-20.
78. Yazici Y, Yazici H. Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis. Clin Exp Rheumatol. 2008 May-Jun; 26(3):449-52.
79. Yazici Y, Sokka T, Pincus T. Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am. 2009 Nov;35(4):723-9.
80. Fuchs HA, Pincus T. Radiographic damage in rheumatoid arthritis: Description by nonlinear models (editorial). J Rheumatol. 1992 Nov;19(11):1655-8.
81. Landewe R, van der Heijde D. Radiographic progression depicted by probability plots: presenting data with optimal use of individual values. Arthritis Rheum. 2004 Mar;50(3):699-706.
82. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008 Sep-Oct; 26(5 Suppl 51):S35-61.
83. Pincus T, Ferraccioli G, Sokka T, et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology. 2002 Dec;41(12):1346-56.
84. Callahan LF, Pincus T, Huston JW III, et al. Measures of activity and damage in rheumatoid arthritis: Depiction of changes and prediction of mortality over five years. Arthritis Care Res. 1997 Dec;10(6):381-94.
85. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin Drug Investig. 2006;26(2):55-62.
86. Rajakulendran S, Gadsby K, Deighton C. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified? Musculoskeletal Care. 2008 Dec;6(4):233-45.
87. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis. 2007 Feb;27(1):044-54.
88. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008 Jun 15;59(6):762-84.
89. Visser K, van der Heijde DM. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol. 2009 Nov-Dec; 27(6): 1017-25.